AUTHORIZED USE
The FDA has authorized the emergency use of PAXLOVID, an investigational medicine, for the treatment of mild-to-moderate COVID-19 in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]) with a positive test for the virus that causes COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, under an EUA.
PAXLOVID is investigational because it is still being studied. There is limited information about the safety and effectiveness of using PAXLOVID to treat people with mild-to-moderate COVID-19.
PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.
Notice: The below links are provided as a resource to our visitors, and do not imply an endorsement or recommendation of a particular test or telehealth provider by Pfizer, nor an endorsement of any Pfizer product by a company, provider, or platform.
Click on the links below to learn about in-office and at-home COVID-19 rapid-testing options.
This is not an exhaustive list of COVID-19 testing options. Please visit
covidtests.gov, a resource provided and managed by the U.S. Department of Health and Human Services, to order free at-home COVID-19 tests and for other related information, including where you may find free testing sites near you.
Pfizer does not own or operate any of the below websites, or the products that they furnish, and Pfizer accepts no responsibility or liability for them.
If you do not have a healthcare provider or your healthcare provider is not available, you may be able to connect with one through telehealth services. You can visit one of the following sites to connect with a healthcare provider by phone, chat, or video.
Pfizer does not own or operate any of these telehealth platforms, or the services they or their providers may furnish, and Pfizer accepts no responsibility or liability for them.
Providers for these telehealth platforms were selected based on their ability to provide COVID-19–related services in a traditional healthcare, physician office, or clinic setting. Providers or telehealth companies do not pay a fee to Pfizer for inclusion on this website.
If these telehealth platforms match users with providers, the selection of a particular provider is determined by the criteria set by the platform and/or provider, not Pfizer. All treatment decisions are at the sole discretion of the provider based on the patient’s individual needs and risk-benefit profile.
FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS
Revised 8/5/22
HOJA INFORMATIVA PARA PACIENTES, PADRES Y
CUIDADORES
Revisado 28 de junio de 2022
FICHE D’INFORMATION POUR LES PATIENTS, LES PARENTS ET LES SOIGNANTS
Révisé le 28 juin 2022
FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS
Revisto 28 de junho de 2022
HOJA INFORMATIVA PARA PACIENTES, PADRES Y CUIDADORES
FICHE D’INFORMATION POUR LES PATIENTS, LES PARENTS ET LES SOIGNANTS
Revised 7/6/22
FACT SHEET FOR HEALTHCARE PROVIDERS
Revised 7/6/22
FOLHETO INFORMATIVO PARA DOENTES, PAIS E PRESTADORES
DE CUIDADOS
Revisto 28 de junho de 2022
صحيفة الحقائق للمرضي والاطباء ومقدمي الرعايه
患者、父母和照护者情况说明书
FACT SHEET FOR HEALTHCARE PROVIDERS
Revised 7/6/22
FACT SHEET FOR HEALTHCARE PROVIDERS
Revised 7/6/22
HOJA INFORMATIVA PARA PROVEEDORES DE ATENCIÓN MÉDICA
Revisado 6 de julio de 2022
FICHE D’INFORMATION DESTINÉE AUX
PROFESSIONNELS DE SANTÉ
Révision 6 juillet 2022
FICHA INFORMATIVA PARA PRESTADORES DE CUIDADOS DE SAÚDE
Revisto 6 de julho de 2022
صحيفة الحقائق لمقدمي الرعاية الصحية
تمت المراجعة 6 يوليو 2022
COVID-19 Preparedness Plan
تمت المراجعة 6 يوليو 2022
Related Pages
PAXLOVID must be prescribed by a licensed healthcare provider and supplied by a government-approved pharmacy or medical facility.
Authentic PAXLOVID, from Pfizer Inc., will include the Pfizer name on the label and will be packaged in 5 aluminum push-through blister cards. Individual doses are not for sale. PAXLOVID will be packaged in a rectangular carton. The carton has a colorless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over, and these repeating features are seen in a contrasting matte finish.
PAXLOVID consists of tablets for a 5-day oral treatment regimen, with morning and evening doses.
NOTE: If you are a patient with moderate kidney disease, you may receive a carton with daily blister cards that have been altered to ensure you receive the correct dose.
Tablet |
Text |
---|---|
nirmatrelvir |
Front: 3CL | Back: PFE |
ritonavir, manufactured by AbbVie |
Front:
|
ritonavir, manufactured by Hetero |
Front: H | Back: R9 |
Pfizer is committed to patient safety and ensuring that people have accurate information about the investigational drug PAXLOVID, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate PAXLOVID to protect patients from products that might be dangerous and lead to serious and life-threatening harm.
If you suspect the product you have received may be counterfeit, contact us at
1-800-438-1985 or visit
www.pfizersafetyreporting.com.
AUTHORIZED USE
The FDA has authorized the emergency use of PAXLOVID, an investigational medicine, for the treatment of mild-to-moderate COVID-19 in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]) with a positive test for the virus that causes COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, under an EUA.
PAXLOVID is investigational because it is still being studied. There is limited information about the safety and effectiveness of using PAXLOVID to treat people with mild-to-moderate COVID-19.
IMPORTANT SAFETY INFORMATION